Pluri (PLUR) Net Cash Flow Growth (3y) (2013 - 2025)
Pluri (PLUR) Net Cash Flow Growth (3y) (2013 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Pluri |
21.85 Mn |
22.34 Mn |
86,000.00 |
23.15% |
| Date | Value |
|---|
| Dec 31, 2025 |
23.15% |
| Sep 30, 2025 |
-9.07% |
| Jun 30, 2025 |
38.69% |
| Mar 31, 2025 |
-69.30% |
| Dec 31, 2024 |
-3.37% |
| Sep 30, 2024 |
39.90% |
| Jun 30, 2024 |
-35.09% |
| Mar 31, 2024 |
-31.45% |
| Dec 31, 2023 |
-27.65% |
| Sep 30, 2023 |
67.76% |
| Jun 30, 2023 |
0.55% |
| Mar 31, 2023 |
-131.62% |
| Dec 31, 2022 |
-52.69% |
| Sep 30, 2022 |
-33.42% |
| Jun 30, 2022 |
-27.97% |
| Mar 31, 2022 |
-39.19% |
| Dec 31, 2021 |
70.68% |
| Sep 30, 2021 |
-277.48% |
| Jun 30, 2021 |
104.33% |
| Mar 31, 2021 |
62.93% |
